CNSX - New Listing - Pivotal Therapeutics Inc. (PVO)

Bulletin: 2011-0510

TORONTO, May 18 /CNW/ - The common shares of Pivotal Therapeutics Inc. have been approved for listing on CNSX.  The Company has 68,986,117 common shares outstanding with a public float of approximately 49.6 million shares.

Pivotal is a re-profiling specialty pharmaceutical company that creates novel uses for currently marketed or near market drugs or therapeutics. Pivotal's first product, VASCAZENTM, is a prescription-only medical food to be used for the clinical dietary management of cardiovascular disease in patients with documented coronary heart disease (CHD), deficient in blood omega-3 fatty acid, Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) levels.

Listing and disclosure documents for Pivotal Therapeutics Inc. will be available in the CNSX Listings Disclosure Hall.

Trading Date: Thursday, May 19, 2011
Symbol: PVO
CUSIP: 72582E 10 4
ISIN: CA 72582E 10 4 3

Applications are being accepted for Market Makers for "PVO ".

SOURCE Canadian National Stock Exchange (CNSX)

For further information:

If you have any questions or require further information please contact Radhika at (416) 572-2000 X 2435 or E-mail: radhika.ramkarran@cnsx.ca

Profil de l'entreprise

Canadian National Stock Exchange (CNSX)

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.